Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares

Rhea-AI Summary

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) has completed its underwritten public offering, raising approximately $402.5 million through the sale of 4,007,936 shares of common stock priced at $63.00 per share, along with pre-funded warrants for 2,380,956 shares. The offering includes an additional 833,333 shares due to underwriters' full exercise of their option. The funds will support Apellis' commitment to developing innovative therapies. J.P. Morgan, Goldman Sachs, and Evercore served as joint book-running managers for the offering, which was facilitated under an automatically effective shelf registration statement.

Positive

• Raised approximately $402.5 million to support business growth and development.
• Successful execution of a public offering demonstrating investor confidence.

Negative

• Potential dilution of existing shares due to the large number of new shares issued.

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants, including the exercise in full by the underwriters of their option to purchase an additional 833,333 shares. The exercise of the option to purchase additional shares increased the amount of gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by Apellis, to approximately $402.5 million.

The public offering consisted of 4,007,936 shares of common stock at the public offering price of $63.00 per share, including 833,333 shares of common stock pursuant to the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase 2,380,956 shares of common stock at the public offering price of $62.9999 per pre-funded warrant.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C. acted as joint book-running managers for the offering. Robert W. Baird & Co. Incorporated and Raymond James & Associates, Inc., acted as co-managers for the offering.

The securities were offered by Apellis pursuant to an automatically effective shelf registration statement that was filed with the Securities and Exchange Commission (“SEC”) on February 22, 2023. This offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Apellis

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases.

Media Contact:
Lissa Pavluk
media@apellis.com
617.977.6764

Investor Contact: 
Meredith Kaya 
meredith.kaya@apellis.com
617.599.8178

FAQ

What is the total amount raised by Apellis Pharmaceuticals in their recent offering?

Apellis Pharmaceuticals raised approximately $402.5 million through its recent public offering.

How many shares of common stock did Apellis Pharmaceuticals offer?

Apellis Pharmaceuticals offered 4,007,936 shares of common stock in the recent offering.

What was the public offering price for the common shares?

The public offering price for the common shares was $63.00 per share.

Who were the joint book-running managers for the Apellis offering?

J.P. Morgan, Goldman Sachs, and Evercore served as the joint book-running managers for the offering.

How many shares were included due to the underwriters' option?

The underwriters fully exercised their option to purchase an additional 833,333 shares.